The purpose of this study is to develop a formulation for a once-a-day peroral application with controlled release of nitrendipine. The second aim of the study is to de®ne by the use of modelling and computer simulation those critical points in the development of the formulation, the knowledge and controlling of which brings a rationalisation in the sense of time and material. #
Introduction
The design of drug formulations is based on the principles of pharmacokinetics, biopharmaceutics and pharmaceutical technology. In accordance with the updated trends, formulations that reduce to the minimum the possibility of undesired toxic eects and increase to the maximum the possibility of desired therapeutic eects should be developed. Therefore a methodology for drug formulations design is needed that would in the ®nal phase ensure the achievement of the set goal in the best possible way. The framework of the methodology is a step-wise iterative procedure that includes the data on pharmacokinetic and biopharmaceutical properties of the drug itself, the data on the therapeutic range of plasma concentrations, the analytical method for the identi®cation of drug concentrations in arti®cial and biological¯uids, the procedures of mathematical modelling and computer simulation, in vitro and in vivo testing procedures and a clearly de®ned purpose of the study. The result of a step-wise iterative procedure is an instruction that contains data on the mode of application and on the formulation with a controlled release of the drug [1] .
Starting points for the development of the nitrendipine pharmacokinetic model
Nitrendipine [2] produces antihypertensive eect through blockade of the calcium conducting channels. After peroral application it is rapidly and completely absorbed in portal blood, while in the liver it is subjected to extensive presystemic metabolism the consequence of which is approximately 25% absorption into the systemic blood circulation. The absolute bioavailability does not depend on the size of the administered doze and on its release rate, what is manifested in linearity of kinetics. It has been proved, that no saturation of the liver enzymes occurs with the doses of 5 to 40 mg. The biological half life of nitrendipine is about 12 h (range 2±24 h). Besides biological variability, dierent sensitivity of analytical methods as a major cause is re¯ected in the great span of this value. Till 1985 (the period of ®rst clinical trials) HPLC analytics was used and its sensitivity is 1±2 mg/l. In the year 1987 the capillary GC-MS analytics was developed and essentially improved the sensitivity up to the range 0,02± 0,1 mg/l. The authors using HPLC analytics reported on biological half life of 3.5 h in an average from 2 to 5 h, while the authors using GC assay determined the value of 10 h in the average (from 9 to 11 h). The in¯uence of the analytical method is also evident in the results of the pharmacokinetic analysis. The HPLC methodology permitted the identi®cation of two phases, while GC analytics drew the attention to the existence of the third phase in the plasma concentration pro®le. This ®nding has a key meaning in understanding the relation between concentration and eect. Namely, in the literature there could not be found any data that would combine the plasma concentration of nitrendipine with the antihypertensive eect. These investigations resulted in the presumption that there exists a correlation between the antihypertensive action and the nitrendipine concentration in the calcium channels. One can hypothesise that there exists the`deep' peripheral compartment (calcium channels?) where the drug accumulates, maintains its pharmacodynamic eect and returns very slowly back to the central compartment. The latter may be the reason for the observed low plasma concentrations in the terminal phase. Moreover, essential cumulation of nitrendipine in the`deep' compartment and considerable oscillations of drug levels in that compartment can be expected irrespective of the release rate of nitrendipine from formulation administered perorally.
Methods
The data base for this study, was taken from the reference study [3] in which the authors investigated the pharmacokinetics of nitrendipine following the application in dierent doses in an intravenous injection (formulation A) and perorally in a gelatinous capsule containing solution (formulation B) as well as in a tablet with instant release (formulation C). Nitrendipine plasma concentrations were determined by HPLC method. Only the plasma concentration pro®le obtained following an intravenous injection of 2 mg of nitrendipine was pharmacokinetically analysed with the method of stripping. Their statement that a twocompartment model (with two phases in the concentration pro®le) represents a satisfactory approximation of nitrendipine pharmacokinetics, served us as a starting point for a gradual development of a model in accordance with the purposes of modelling. As a tool for developing a model, compartmental pharmacokinetic modelling [4] and digital simulation package Simulink [5, 6] were chosen.
Results and discussion
In Fig. 1 a model is shown that can be used multipurposely with respect to dierent modes of administration and dierent interpretations of the distribution of nitrendipine in the body.
The model that contains the compartments C P , U d1 and U e2 illustrates the starting situation (intravenous application in the form of an injection, a two-compartment model with the central compartment and one peripheral compartment, systemic metabolism). The results of simulation are shown in Fig. 2 .
As the last measurement at time 8 h is already on the limit of detection with the HPLC method the authors could not experimentally determine the course of plasma concentrations in the time interval between the 8th and 24th hour. So, there exists the possibility that the course foreseen with the two-compartment model may also be dierent. In regard to the suggestion Fig. 1 . Compartmental pharmacokinetic model of nitrendipine. U T levels in the tablet, U GI levels in the gastrointestinal tract, U GIC cumulative levels in the gastrointestinal tract, U L levels in the liver, U P levels in the plasma (the central compartment), C P plasma concentrations, V C volume of distribution of the central compartment, U d1 levels in the`shallow' peripheral compartment, U d2 levels in the`deep' peripheral compartment, U e2 levels of metabolites after presystemic metabolism, U PO levels of metabolites after systemic metabolism, D PO peroral dose, D IV intravenous dose, k s release rate constant, k al absorption rate constant into the portal blood circulation, k la and k À la absorption rate constants into the central blood circulation, k d1 and k À d1 distribution rate constants into the`shallow' compartment, k d2 and k À d2 distribution rate constants into the`deep' compartment, k e1 and k e2 metabolising rate constants.
we wished to verify the hypothesis whether the three-compartment model eventually enables an equal quality of ®t in the interval between 0th and 8th hour, while in the interval between 8th and 24th hour the concentration of nitrendipine in plasma does not decrease to a negligible value. We chose a model that contains compartments C P , U d1 , U d2 and U e2 (Fig. 3) to illustrate the new situation (intravenous application in the form of an injection, three- The results of simulation on Fig. 3a con®rmed our hypothesis since the goodness of ®t in the central compartment is comparable to that in Fig. 2a . Model response showed that in the time interval between the 8th and 24th hour the nitrendipine levels are signi®cantly high only in the compartment U d2 . Furthermore, the course of nitrendipine levels in this compartment may support the statement that the antihypertensive eect of nitrendipine correlates better with the concentrations on the site of action (calcium channels) than with plasma concentrations, if we suppose that calcium channels are located in the U d2 compartment.
As the purpose of our investigation was to develop a peroral formulation with a controlled release of nitrendipine, we continuing our investigation extended the three-compartment model with the compartments that enable the simulation of peroral application (the compartments U T , U GI , U GIC ) and the simulation of presystemic metabolism in the liver (the compartments U L and U e1 ). Two dierent gastrointestinal compartments have been included in the model: a cumulative one, which gives information similar to the in vitro dissolution pro®le of the drug and the actual one, which simulates the levels comparable to those present in vivo. The results of investigations concerning the in¯uence of drug formulation, i.e. the release rate on the nitrendipine levels in all the compartments of the model in Fig. 1 following the administration of gelatinous capsule (formulation B) and tablet with instant release, with 30 mg nitrendipine each are shown in the Figs. 4 and 5. Table 1 summarises the values of identi®ed nitrendipine pharmacokinetic parameters. As seen from Figs. 4 and 5 and Table 1 , optimal accordance between the model response and the experimental data for both peroral formulations was reached only by modulating the parameter k s , what indicates that release is the process that exerts a deciding in¯uence on the pharmacokinetics of the drug and herewith also on its pharmacological eect. The in¯uence of the release rate is to a high degree manifested in the plasma concentration pro®le. More interesting results are shown when analysing the pro®les in U d2 . In this case the in¯uence of the release rate is manifested in essentially smaller degree. The levels in U d2 are comparable at 24 h and they range about 1 mg regardless of the release rate. As well as the reason for the change of the plasma concentration pro®le for the formulations B and C, which was identi®ed uniquely, also behaviour after multiple dosing, i.e. in cases when chronic therapy is indicated can be predicted. It is known that a change in release rate in¯uences only the extent of oscillation of drug levels and not the average steady state values of drug levels in those compartments where cumulation occurs. This is also con®rmed by the results of simulation of multiple dosing of a 20 mg nitrendipine dose in formulations B and C, shown in Fig. 6 .
It is obvious from Fig. 6a that nitrendipine does not cumulate in plasma (central compartment) after multiple dosing. Furthermore, the oscillations of nitrendipine concentrations are considerable and the average values dier signi®cantly. To this statement it can be added that nitrendipne also does not cumulate in the`shallow' compartment, while the cumulation is essential in the`deep' compartment irrespective of the release rate from the formulation administered perorally. In Fig. 6b the pro®les in U d2 after multiple dosing are compared with respect to the dierence in the release rate. The average level in the steady state is equal (1.25 mg for a 20 mg dose), while the oscillations are the function of the release rate. It can be seen that the dierence in oscillations is much smaller than the one observed in plasma. The conclusion drawn from the results of simulation of multipleperoral dose regimen are supported by ®ndings of Johnson et al. [7] . He demonstrated that blood pressure in patients with essential hypertension continued to decline over a 6 h period after peroral dosing as the plasma concentration of nitrendipine decreased. By the aid of supposition that calcium channels are located in the`deep' peripheral compartment we provide the explanation that essential prolongation of pharmacodynamic eect is a result of high nitrendipine levels in thè deep' peripheral compartment, i.e. calcium channels during the period of 24 h. In the case of plasma concentration pro®le this period amounts to only 8 h.
Overall, the results of simulation permitted us the following conclusions: there is justi®ed a development of a formulation for peroral application releasing nitrendipine with ®rst order rate constant ranging between 0.5 and 1.5 h À 1 , with respect to low solubility of nitrendipine it is essential to prepare a formulation which would release at least 90% of the dose in 10 h at the very latest and there is justi®ed the once-a-day application of nitrendipine in the formulation with controlled release in the case of chronic therapy.
Summary
The purpose of this contribution is to present the role of pharmacokinetic modelling and computer simulation in the design of controlled release formulations and to de®ne those critical points in the procedure, the knowledge and controlling of which brings a rationalisation in the timely and material sense. The approach is illustrated by the design of peroral formulation with controlled release of nitrendipine, an antihypertensive drug from dihydropyridine series.
Nitrendipine is rapidly and completely absorbed in portal blood after peroral application, while in the liver it is subjected to extensive presystemic metabolism, the consequence of which is approximately 25% absorption to systemic blood circulation. The absolute bioavailability does not depend on the size of the administered dose and on its release rate. When analysing plasma concentration pro®les by the method of residuals, the HPLC methodology permitted the identi®cation of two phases, while GC/MS with improved sensitivity drew the attention to the existence of the third phase in the plasma concentration pro®le resulting in the signi®cant prolongation of biological half life. This ®nding had a key meaning in understanding the relationship between concentration and eect, and represented a critical point in the process of nitrendipine formulation design. Namely, in the literature there could not be found any data that would combine the plasma concentration of nitrendipine with antihypertensive eects. This investigation resulted in the presumption that there exists a correlation between the antihypertensive action and the nitrendipine concentration in the calcium channels. We hypothesised that there exists a`deep' compartment (calcium channels?) where the drug accumulates, maintains its pharmacodynamic eect and returns very slowly back to the central compartment. The latter may be the reason for the observed low plasma concentrations in the terminal phase. Moreover, we expected essential cumulation of nitrendipine in the`deep' compartment and considerable oscillations of drug levels in the compartment, irrespective of the release rate of nitrendipine from formulation administered perorally. For the development and application of nitrendipine pharmacokinetic study, the data base was taken from the reference study, in which authors investigated the pharmacokinetics of nitrendipine following the application of dierent doses in dierent dosage forms. Pharmacokinetic compartmental analysis based on digital simulation package Simulink was carried out with the use of the composed two-(central and peripheral) and three-(central, shallow and deep) compartment model. The results of simulation in the case of single-dose regimen con®rmed our hypothesis regarding the structure of the model, since the goodness of ®t in central compartment (plasma) in the case of three compartment model was excellent and antihypertensive eect correlated better with the course of nitrendipine levels in the deep compartment. This ®nding led us to the supposition that calcium channels are located in the deep compartment. Consequently, the release of nitrendipine from peroral formulation and the dosage interval must be adjusted to provide optimal pro®le in this compartment. The results of simulation in the case of multiple dose regimen, con®rming our hypothesis regarding cumulation and oscillations in the deep compartment, permitted us the following conclusions: there is justi®ed a development of a formulation for peroral application releasing nitrendipine with ®rst order rate constant ranging between 0.5 and 1.5 h À 1 , with respect to low solubility of nitrendipine it is essential to prepare a formulation which would release at least 90% of the dose in 10 h at the very latest and there is justi®ed the once-a-day application of nitrendipine in the formulation with controlled release in the case of chronic therapy.
